Exicure reported a net loss of $16.9 million for fiscal year 2023, compared to a $2.6 million loss in 2022. Revenue dropped to zero from $28.8 million in the prior year following the termination of collaboration agreements. Operating expenses decreased to $15.0 million from $30.7 million, reflecting the suspension of R&D activities and workforce reductions.The company's cash position deteriorated significantly, with cash and equivalents declining to $0.8 million as of December 31, 2023, compared to $8.6 million at the end of 2022. Management acknowledged substantial doubt about the company's ability to continue as a going concern, noting that substantial additional funding is needed in the very near term to satisfy existing obligations and continue operations.Following a strategic shift announced in September 2022, Exicure has halted all research and development activities and is now exploring strategic alternatives, including potential transactions with partners in industries unrelated to its historical operations. The company is also appealing a Nasdaq delisting determination and faces multiple compliance issues including minimum bid price and stockholders' equity requirements.

Exicure reported a net loss of $16.9 million for fiscal year 2023, compared to a $2.6 million loss in 2022. Revenue dropped to zero from $28.8 million in the prior year following the termination of collaboration agreements. Operating expenses decreased to $15.0 million from $30.7 million, reflecting the suspension of R&D activities and workforce reductions.The company's cash position deteriorated significantly, with cash and equivalents declining to $0.8 million as of December 31, 2023, compared to $8.6 million at the end of 2022. Management acknowledged substantial doubt about the company's ability to continue as a going concern, noting that substantial additional funding is needed in the very near term to satisfy existing obligations and continue operations.Following a strategic shift announced in September 2022, Exicure has halted all research and development activities and is now exploring strategic alternatives, including potential transactions with partners in industries unrelated to its historical operations. The company is also appealing a Nasdaq delisting determination and faces multiple compliance issues including minimum bid price and stockholders' equity requirements.